Today’s guest post comes from Logan Melchione, Vice President of Patient Affordability at Paysign.
Logan examines how pharmaceutical manufacturers must rethink copay assistance in an era affected by maximizers, accumulators, and intensifying payer scrutiny. She argues that brands can both gain a strategic advantage and safeguard adherence by embracing claims-based precision, real-time adaptability, and transparent program design.
Request an analysis of your copay assistance program by emailing Paysign at [email protected] or by visiting paysign.com/rx.
Read on for Logan’s insights.
Read more »
